natgillin/translations-raw huggingface dataset:
(100 mg ritonavir to gange daglig)
50 μg intranasal 4 times daily (100 mg ritonavir BID)
(100 mg til 200 mg per-oralt
(100 mg to 200 mg oral BID in
(100 ml og 250 ml hætteglas)
[100 and 250 ml vials]
(100 or 150c µg/uge)
150c µg/week)
(10000 IE/ml)
(10000 IU/ml)
(10000 IE/ml)
IU/ml)
(10000 IU/ml)
yringe (glass)
(108; 277)
193mL p<0.001 (108, 277)
(11,1-15,0)
24.0 mo
(116/390)
interferon alpha/ribavirin
(11mikrogram) /
(11micrograms)/
(12 uger)
(12 weeks)
(12 uger)
weeks)
(12,0 vs 15,0 måneder; p  0,6267)
(12.0 vs 15.0 months; p 0.6267)
(12,0; 23,9)
18.0% p<0.001 (12.0, 23.9)
(120 doser)
(120 doses)
(127; 294)
210mL p<0.001 (127, 294)
(13,0; 25,6)
19.3% p<0.001 (13.0, 25.6)
(13,1-40,3)
(13.1, 40.3) p=0.0003
(13,4-24,6)
n=106 11.7 (10.2-17.4)
(13,4-24,6)
n=128 15.7
(14,6 % vs.
(14.6% vs 36.3%)
(14,8; NE)
(14.8, NE)
(1400 mg to gange
Fosamprenavir (1400 mg BID)
(150 mg en gang dagligt/600 mg en
(500 mg twice daily/600 mg once
(16,2 vs 17,5 måneder; p 0,3769)
(16.2 vs 17.5 months; p 0.3769)
(16,6-21,7)
Mediana response duration
(17,5 vs 14,3 måneder; p 0,0609)
(17.5 vs.14.3 months; p 0.0609)
(17,5 vs 15,0 måneder; p 0,0584)
(17.5 vs.15.0 months; p 0.0584)
(178; 426)
302mL p<0.001 (178, 426)
(18,0; 34,3)
26.2L/min p<0.001 (18.0, 34.3)
(18-36 år) (legemsvægt 60 kg eller mindre)
(18-36 years of age) (body weight less than or equal to 60 kg)
(18-36 år) (legemsvægt over 60 kg og mindre end eller lig med 90 kg)
(18-36 years of age) (body weight greater than 60 kg and less than or equal to 90 kg)
(1; 270)
136mL p=0.048 (1, 270)
(2 %,
p- value
(2 enkeltdoser/600 mg én gang dagligt)
(2 mg single dose/600 mg once daily)
(2 mg enkeltdoser/600 mg én gang
(2 mg single dose/600 mg once daily)
(2 mg enkeltdosis)/elbasvir
(2 mg single dose)/
(2 poser)
dispensed
(2 uger)
(2 weeks)
(2 x 1.000 mg)
(2 x 1000 mg)
(2) Efter dialyse anbefales 250 til 500 mg som supplerende dosis.
(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.
(2) Efter dialyse anbefales 5 til 10 mg/kg. (0,05 til 0,10 ml/kg) som supplerende dosis.
(2) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
(2) Imatinib 36 mdr.
(2) Imatinib 36 MO:
(2) Lad være med at
(2) Do not touch
(2) Lad være med at røre ved den røde knap.
(2) Do not touch red button.
(2) lokale bivirkninger associeret med intravenøs administration
(2) local adverse events associated with intravenous administration
(2,08-3,12)
ombitasvi
(2,0; 14,8)
8.4% p=0.010 (2.0, 14.8)
(2,31-2,86)
patients for clinical effects.
(2,4 sekunder bedre), og tid til at gå ned ad 4 trin (1,6 sekunder bedre), figur 3.
4 stairs (better by 2.4 seconds), and time to descend 4 stairs (better by 1.6 seconds), Figure 3.
(2,40-4,17)
the additional
(2,5 mg – 20 mg), hvor administration af nitrat skønnes som en medicinsk nødvendighed i en livstruende situation, mindst være gået 48 timer efter den sidste dosis CIALIS, før administration af nitrat overvejes.
20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of CIALIS before nitrate administration is considered.
(2,8-4,1)
(2.8 to 4.1)
(2,9-5,6)
(2.9 to 5.6)
(2./3. gang)
(2nd/3rd time)
(2.668 mg enkeltdosis)/elbasvir
(2,668 mg single
(20 doser)
containers (20 doses)
(20 mg enkeltdosis)/elbasvir
(20 mg single
(20 mg enkeltdosis)/grazoprevir
(20 mg single
(20 ml og 50 ml)
[20 and 50 ml vials]
(20,2 % vs.
(20.2% vs 47.5%)
(20,9-51,5)
35.5 (19.3-NA)
(20-120 mg en gang
(20-120 mg once
(20-150 mg en gang
(20-150 mg once
(20/120 mg tablet, 6 doser af 4 tabletter
(20/120 mg tablet, 6 doses of 4
(200 mg en gang
(150 mg once
(200 mg en gang dagligt)
(200 mg once
(200 mg en gang dagligt)
(50 mg once daily)
(200 mg en gang dagligt)
once daily)
(200 mg enkeltdosis)
(200 mg single
(200 mg hver 12. time/600 mg én gang
(600 mg once daily/600 mg once
(200 mg hver12. time/600 mg én gang
(200 mg q12h/600 mg once daily)
(200 mg q12h/600 mg én gang dagligt)
(200 mg q12h/600 mg once daily)
(200 mg q12h/600 mg én gang dagligt)
(600 mg once daily/600 mg once
(200 mg to gange dagligt/400 mg én
(200 mg twice daily/400 mg once
(2000 IE/ml)
(2000 IU/ml)
(21,7; 34,8)
28.2L/min p<0.001 (21.7, 34.8)
(22,3; 41,7)
33.5L/min p<0.001 (22.3, 41.7)
(22,5; 38,9)
30.7L/min p<0.001 (22.5, 38.9)
(23 mg/26 mg og 46 mg/53 mg i syv på hinanden følgende doser) blev vurderet i en randomiseret, placebokontrolleret, dobbeltblindet overkrydsningsundersøgelse med en supplerende åben arm med aktivt sammenligningsstof (400 mg moxifloxacin) hos 36 raske forsøgspersoner.
The effects of supra-therapeutic doses of dextromethorphan /quinidine (23 mg /26 mg and 46 mg / 53 mg, for 7 consecutive doses) on QTc prolongation were evaluated in a randomised, placebo- controlled, double-blind, crossover design with an additional open-label positive control (400 mg moxifloxacin) arm in 36 healthy volunteers.
(24 uger)
weeks)
(24,7-31,1)
19.2 mo (17.0, 21.0)
(24,8; 41,1)
32.9L/min p<0.001 (24.8, 41.1)
(240 g én gang dagligt/600 mg én gang
Diltiazem/Efavirenz (240 mg once daily/600 mg once daily)
(240 mg én gang dagligt/600 mg én gang
Diltiazem/Efavirenz (240 mg once daily/600 mg once daily)
(25 mg en gang
(25 mg once daily)/
(25.000– 49.999/mm3)
(25,000– 49,999/mm3)
(250 ml/500 ml)
{250ml/500ml}
(26,5; 40,0)
33.3L/min p<0.001 (26.5, 40.0)
(3 MIE TIW)
Interferon alfa-2b (3 MIU TIW)
(3 MIE TIW) + ribavirin (800 mg)
ribavirin (800 mg)
(3 år efter vaccinati on)
(3 years post vaccination)
(3 år efter vaccinatio n)
(3 years post vaccination)
(3) middel-opfølgningstid på 44 måneder efter første vaccinedosis
(3) mean follow-up of 44 months post dose 1
(3) Tryk let
(3) Briefly press
(3,21-4,97)
ombitasvi r/paritapr
(30 ml enkeltdosis/400 mg enkeltdosis)
(30 mL single dose/400 mg single
(300 mg en gang
(300 mg once
(300 mg én gang dagligt)
(300 mg once daily)
(300 mg én gang dagligt/600 mg én
(300 mg once daily/600 mg once
(300 mg én gang dagligt/600 mg én
Telaprevir/Efavirenz (1,125 mg q8h/600 mg once daily)
(300 mg én gang dagligt/600 mg én gang
Clarithromycin/Efavirenz (500 mg q12h/400 mg once daily)
(328/407
Negative
(3333 IU/ml)
yringe (glass)
(35,3-48,3)
43.1 mo (35.3, 48.3)
(35-42 år) (legemsvægt 50 kg eller derover)
(35-42 years of age) (body weight greater than or equal to 50 kg)
(37,8 måneder)
(37.8 months)
(38-86)2
Haematologic
(39 ud af 150) af de børn, der fik ondansetron alene.
150) of children given ondansetron alone.
(4 kapsler/~ 6,5 ml to gange
(4 capsules/~6.5 ml twice daily
(4 uger)
(4 weeks)
(4) p-værdi = 0,0009 (5) VE var 100 % (95 % CI 74,3-100; 0 versus 16 tilfælde) i ATP-kohorten
(4) p-value=0.0009 (5) in the ATP cohort VE was 100% (95% CI: 74.3-100; 0 versus 16 cases)
(4) Tæl
(4) Count slowly
(4,0 - 6,1)
(4.0 to 6.1)
(4,3; 16,8)
10.6% p<0.001 (4.3, 16.8)
(4-[N-maleimidomethyl] cyclohexan-1-carboxylat) er kovalent bundet til DM1, en mikrotubulær hæmmer.
(4-[N-maleimidomethyl] cyclohexane-1-carboxylate).
(4-[N-maleimidomethyl]-cyclohexan-1-carboxylat) er kovalent bundet til den mikrotubulære hæmmer DM1 (et maytansinderivat).
MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate).
(4. gang)
(4th time)
(40 mg en gang
(40 mg once daily)/
(40 mg enkeltdosis)/elbasvir
(40 mg single
(40 mg)/8 ml; 8 ml (1000 E/ml-5
8 ml (1000 U/ml
(400 mg b.i.d. / 100 mg b.i.d. / 245 mg q.d.)
Lopinavir/ritonavir / tenofovir disoproxil (400 mg b.i.d. / 100 mg b.i.d / 245 mg q.d.)
(400 mg enkeltdosis)/elbasvir
(400 mg single
(400 mg oralt en gang dagligt)/
(400 mg PO once
(400 mg to gange
(400 mg twice
(400 mg to gange dagligt/300 mg én
(200 mg twice daily/400 mg once
(400 mg to gange dagligt/300 mg én
(400 mg twice daily/300 mg once
(400 mg én gang dagligt/600 mg én gang
Carbamazepine/Efavirenz (400 mg once daily/600 mg once daily)
(400/100 mg to gange dagligt/600 mg én
(400/100 mg twice daily/600 mg
(400/100 mg to gange dagligt/600 mg én
(400/100 mg twice daily/600 mg once daily)
(400/100 mg to gange dagligt/600 mg én
(800 mg q8h/200 mg once daily)
(40000 IE/ml)
(40000 IU/ml)
(40000 IE/ml)
IU/ml)
(40000 IU/ml)
yringe (glass)
(402/709
Positive
(43,3 hændelser/1.000 patientår), p=0,0023, og versus de samlede grupper, der fik monoterapi med et sulfonylurinstof eller insulin (40,1 hændelser/1.000 patientår), p=0,0034
p = 0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p = 0.0034
(46,8-55,9)
(46.8 to 55.9)
(47,7 %)
OR=2.34
(5 EL.E/ml)
(5 EL.U/ml)
(5 ml solvens)
(5 ml solvent)
(5 ml solvens) pulver og solvens til injektions-/infusionsvæske, opløsning
(5 ml solvent) powder and solvent for solution for injection/infusion
(5 år efter vaccination)
(5 years post vaccination)
(5) Kontrollér
(5) Check
(5) Kontrollér vinduet.
(5) Check window
(5) Progression af præeksisterende pankreatisk adenokarcinom med KRAS-mutation
(5) Progression of pre-existing pancreatic adenocarcinoma with KRAS mutation.
(5,5 mikrogram)
(5.5 micrograms)
(5,8; 18,8)
12.3L/min p<0.001 (5.8, 18.8)
(5,9)
Change LSM (SE)
(50 doser)
(50doses)
(50 KIE/ml) solvens: 5 ml
KIU/ml) solv.: 5 ml
(50 KIE/ml); solvens: 2 ml
KIU/ml); solv.: 2 ml
(50 KIU/ml); solvens: 1 ml
KIU/ml); solv.: 1 ml
(50 mg en gang
(1,000 mg single
(50 mg en gang
(50 mg once daily)/
(50 mg en gang dagligt)
(50 mg once daily)
(50 mg en gang dagligt)/
elbasvir (50 mg
(50 mg enkeltdosis)
dose)/ elbasvir
(50 mg enkeltdosis)/
dose)/ elbasvir
(50 mg enkeltdosis)/elbasvir
(50 mg single
(50 mg enkeltdosis)/grazoprevir
dose)/ elbasvir (50
(50 mg én gang dagligt/600 mg én gang
(50 mg once daily/600 mg once
(500 mg q12h/400 mg én gang
Itraconazole/efavirenz (200 mg q12h/600 mg once daily)
(500 mg to gange dagligt/600
Boceprevir/Efavirenz (800 mg 3 times daily/600 mg once daily)
(500/100 mg to gange daglig)
Tipranavir/ritonavir (500/100 mg BID)
(500/125 mg to gange dagligt/600 mg én gang dagligt)
(400/100 mg twice daily/600 mg once daily)
(52 uger)
(52 weeks)
(52,8-60,9)
56.4 mo (52.8, 60.9)
(6 < 12 år
Older children (6 <12 years)
(6,2; 18,1)
12.1% p<0.001 (6.2, 18.1)
(6,7-9,8)
ORR (CR+PR)
(6,9-8,5)
(6.9 to 8.5)
(6. til 12. time for patienter
(6 to 12 hours for patients under the age
(6. til 12. time for patienter under 6 år),
(6 to 12 hours for patients under the
(6. til 12. time for patienter under 6 år),
(6 to 12 hours for patients under the age
(6. til 24. time for patienter
(6 to 24 hours for patients under the age
(6. til 24. time for patienter under 6 år),
(6 to 24 hours for patients under the
(6. til 24. time for patienter under 6 år),
(6 to 24 hours for patients under the age
(60,6 - 69,7)
(60.6, 69.7) (p<0.0001)
(600 mg intravenøs
(600 mg IV single
(600 mg oral
(600 mg PO single
(600 mg oralt en gang
(600 mg PO once
(600 mg to gange
(600 mg twice
(600 mg én gang dagligt/600 mg én gang
(600 mg once daily/600 mg once
(600 mg én gang dagligt/600 mg én gang dagligt)
(600 mg once daily/600 mg once
(600 mg/200 mg/245 mg q.d.)1
ORAL CONTRACEPTIVES
(61,9, 79,8)d
(61.9, 79.8)d
(63,6, 81,0)d
(63.6, 81.0)d
(7,0-8,9 g/dl eller ethvert fald
(7.0-8.9 g/dl or any decrease
(7,1; 14,0) p < 0,0001
(7.1, 14.0) p<0.0001
(7,9; 21,3)
14.6L/min p<0.001 (7.9, 21.3)
(70 mg/2.800 IE) versus alendronat alene (henholdsvis 12 % versus 32 %) efter uge 15.
32 %, respectively), through week 15.
(70,8; 87,3) (78m6; 92m8)
(70.8; 87.3) (78.6; 92.8)
(73; 339)
206mL p=0.003 (73, 339)
(75 mg/m² på førstedagen) i kombination med cisplatin (C) (75 mg/m² på førstedagen) og 5-fluoruracil (F) (750 mg/m² pr. dag i 5 dage) eller cisplatin (100 mg/m² på førstedagen) og 5-fluoruracil (1.000 mg/m² pr. dag i 5 dage).
(750 mg/m² per day for 5 days) or cisplatin (100 mg/m² on day 1) and 5-fluorouracil (1000 mg/m² per day for 5 days).
(750 mg q8h/600 mg én gang dagligt)
(750 mg q8h/600 mg once daily)
(750 q8h/600 mg én gang dagligt)
(750 mg q8h/600 mg once daily)
(8,1-10,6)
N=106
(8,1-10,8)
p-valuea
(8,6-14,1)
N=76
(8,94-15,98)
dose of
(8-24 mg/2-6 mg en gang
(8-24 mg/2-6 mg
(8. til 24. time for patienter under 6 år)
(8 to 24 hours for patients under the
(8. til 24. time for patienter under 6 år)
(8 to 24 hours for patients under the age
(800 mg 3 gange dagligt/600 mg en
(400 mg single dose/ - )
(800 mg q8h/200 mg én gang
Indinavir/efavirenz (800 mg q8h/200 mg once daily)
(833 IE/ml)
0.270 mL (833 IU/mL)
(87; 258)
172mL p<0.001 (87, 258)
(9 mg/m2) P (60 mg/m2)
M (9 mg/m2) P (60 mg/m2)
(9,7-15,0)
(9.7 to 15.0)
(9,8-15,9)
(9.8 to 15.9)
(90 % konfidensinterval 38 - 123 %)
(90 % CI 38-123 %)
(90 % konfidensinterval 44 - 131 %)
(90 % CI 44-131 %)
(905 stamme): mindst 3,0 log 10
felis (905 strain): at least 3.0 log 10
(90Y) Yttriumchlorid Akt.: (Y) GBq/hætteglas
Yttrium (90Y) chloride Act.: (Y) GBq/vial
(95 %
(95% CI)
(95 % - CI)
(95% CI)
(95 % C.I.: 4,9; 9,5) for gruppen, der fik cisplatin alene og med et risikoforhold på 0,75 (0,49; 1,16).
9.9 months (95 % C.I.: 7, 12.6) versus 6.3 months (95 % C.I.: 4.9, 9.5) for the cisplatin arm with a hazard ratio of 0.75 (0.49, 1.16).
(95 % CI)
(%) (95% CI)
(95 % CI)
(95% CI of
(95 % CI)
8.46
(95 % CI)
90.07
(95 % CI)
95 % CI for median
(95 % CI)
Difference† (95 % CI)
(95 % CI)
nCR n (%)
(95 % CI)
Subjects with mean daily
(95 % CI) (64,1-85,4) (63,1-80,0)
(95% CI) (64.1, 85.4) (63.1, 80.0)
(95 % CI)D)
(95% CI)D)
(95 % CI: 24,1-51,9%)
(95% CI: 24.1-51.9%)
(95 % CI: 51,3 – 84,2 %)
(95% CI: 51.3-84.2%)
(95 % CI: 59,9 – 78,1 %)
(95% CI: 59.9-78.1%)
(95 % CI: 68,2 – 83,5 %)
(95% CI: 68.2-83.5%)
(95 % CIc)
(95% CIc)
(95 % konfidens-
(95 % CI)
(95 % konfidensinterval [CI])
(95 % Confidence interval [CI])
(95 % konfidensinterval)
(95 %CI)
(95 % konfidensinterval)
(95% CI)
(95 % konfidensinterval)
(months) (95 %CI)
(95 % konfidensinterval)
response* (95 % CI)
(95 % konfidensinterval)
Treatment difference
(95 %-CI)
(95 % CI)
(95 %-CI)
(95% CI)
(95 %CI)
(months)
(95 %CI)
18.4
(95 %CI) Hazard ratio (95 %CI)
Hazard ratio (95% CI)
(95% CI)
chemotherapy (%)
(95% CI)
Rate ratio (95% CI)
(95% CI) (14,8; 24,2) (8,8; 16,8)
(95% CI) (14.8, 24.2) (8.8, 16.8)
(95% CI)#
(95% CI) #
(95% konfidensinterval)
(95 % CI)
(95% konfidensinterval) for median
Median DoR (months) (95% CI) for median
(95%-CI)
(95% CI)
(97,5 % CI)
(97.5% CI)
(< 0,001)
Placebo
(< 100 kopier/ml ved PCR), forbedring i leverinflammation og normalisering af ALAT, og var opretholdt ved måling 6 måneder efter afsluttet behandling.
(< 100 copies/mL by PCR), improvement in hepatic inflammation, and normalisation of ALT, and was sustained when measured 6 months after the end of treatment.
(< 25.000/mm3)
(< 25,000/mm3)
(<100 mg 2,6 %; 100-200 mg: 3,5 %; >200mg: 4,9 %), ligeledes var forekomsten af større blødninger for placebo+ASA (<100 mg: 2,0 %; 100-200 mg: 2,3 %; >200 mg: 4,0 %).
(< 100 mg: 2.6%; 100-200 mg: 3.5%; >200 mg: 4.9%) as was the major bleeding event rate for placebo+ASA (< 100 mg: 2.0%; 100-200 mg: 2.3%; >200 mg: 4.0%).
(= least squares) (SE)
93.6 (11.71)
(> 7,8 gange AUC hos patienter behandlet med ADD).
>1 year of dosing (≥7.8 times the AUC in patients administered the RDD).
(>1/10.000 til
(≥ 1/10,000 to
(^)Tigecyclin har nedsat in vitro aktivitet over for Proteus, Providencia og Morganella spp.
(^)Tigecycline has decreased in vitro activity against Proteus, Providencia, and Morganella spp.
(A ml Busilvex) x (10) = B ml infusionsvæske
(A ml Busilvex) x (10) = B ml of diluent
(A ml Busilvex)x(10) = B ml infusionsvæske
(A ml Busilvex) x (10) = B ml of diluent
(a) Cimzia administeret hver 2. uge forudgået af en støddosis på 400 mg ved uge 0, 2 og 4
(a) Cimzia administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4
(a) Cimzia alle doseringsregimer = data fra Cimzia 200 mg administeret hver 2. uge forudgået af en støddosis på 400 mg ved uge 0, 2 og 4 og fra Cimzia 400 mg administreret hver 4. uge forudgået af en støddosis på 400 mg ved uge 0, 2 og 4 (b) Resultater fra det randomiserede sæt (c) Wald p-værdier er angivet for sammenligning af behandlingerne under anvendelse af logistisk regression med behandling og region som faktorer.
(a) Cimzia all dosing regimen = data from Cimzia 200 mg administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 plus Cimzia 400 mg administered every 4 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 (b) Results are from the randomized set (c) Wald p-values are quoted for the comparison of treatments using logistic regression with factors for treatment and region.
(a) Patienterne blev ikke censureret ved tidspunktet for skiftet
(a) Patients were not censored at the time of cross-over
(a) Tilstræbt daglig dosis, (b) Gns. (SD), (c) analyse-population (mITT); MMRM model for forandring fra udgangspunkt til endepunkt inklusiv behandling, region og besøg som faste påvirkninger, og udgangspunktsværdi som en kovariant; (d) tilstræbt daglig dosis på 100 mg; (e) analyse-population (mITT): data er præsenteret som antallet (procentdel) af patienter i hver gruppe der opfylder respondent-definitionen, (f) chi-square test af sandsynlighedsratio hos behandlingsgruppen sammenlignet med placebo ved brug af en logistisk regressionsmodel med fastsat effekt for behandling og land.
(a) Daily targeted dose, (b) Mean (SD), (c) analysis population (mITT); MMRM model for change from Baseline to Endpoint includes treatment, region, and visit as fixed effects, and baseline value as a covariate; (d) target dose of 100 mg/day; (e) analysis population (mITT); data are presented as the number (percentage) of patients in each group meeting the responder definition (f) chi-square test of the odds ratio of the treatment groups compared to placebo using a logistic regression model, with fixed effects for treatment and country.
(a)Intensiteten af de kliniske bivirkninger graderet efter Common Terminology Criteria for Adverse Events v4.0 (CTC-AE).
(a) The intensity of clinical adverse events graded by the Common Terminology Criteria for Adverse Events v4.0 (CTC-AE).
(A-Resistente patienter)
(A-Resistant Patients)
(A-Responsive patienter)
(A-Responsive Patients)
(abacavirkomponent).
component).
(abacavirsulfat / lamivudin / zidovudin) tabletter Hav altid dette kort med dig
TRIZIVIR (abacavir sulfate / lamivudine / zidovudine) Tablets Carry this card with you at all times
(administreret
apart)
(administreret
Mechanism:
(administreret
time)
(af dyb, partiel og fuld tykkelse)
(deep partial and full thickness)
(akut) nyresvigt (alvorlig nyresygdom)
(acute) renal failure (severe kidney disorder)
(Al/Aclar/PVAc/PVC)
EU/1/04/292/007
(Al/Aclar/PVAc/PVC)
EU/1/04/292/008
(ALAT)
(ALT)
(ALAT) eller
Clearance
(ALAT,
Very common
(almindelig - kan berøre op til 1 ud af 10 patienter)
(common - may affect up to 1 in 10 people)
(Almindelig, ≥ 1/100 til < 1/10)
(Common, ≥1/100 to <1/10)
(Almindelige - kan påvirke op til 1 ud af 10 patienter)
(Common - may affect up to 1 in 10 people)
(Almindelige - kan påvirke op til 1 ud af 10 patienter) svært, udbredt udslæt.
(Common - may affect up to 1 in 10 people) severe wide-spread rash.
(alu/alu)
EU/1/04/304/003
(alu/alu)
EU/1/04/304/004
(alu/alu)
EU/1/04/304/005
(alu/alu)
EU/1/04/304/006
(alu/alu)
EU/1/04/304/007
(alvorlig 0,7 %); Hudreaktioner (G3/4:0,2 %)
Nail disorders (severe: 0.7%);
(Amprenavir uden ritonavir)
(Amprenavir without
(antal sår)
(Number of wounds)
(anvendes sammen med ydre æske med 2 sæt af 3 bestanddele)
(used with outer carton of 2 sets of 3 constituents)
(anvendes til at forebygge og behandle mavesår, halsbrand og opstød)
(used to prevent and treat stomach ulcers, heartburn, acid reflux disease)
(ASAT)
(AST)
(ASAT)
aminotransferase
(atazanavir 300 mg 1 gang
(atazanavir 300 mg once daily
(atazanavir 300 mg 1 gang dagligt
(atazanavir 300 mg once daily with
(atazanavir 300 mg og ritonavir
(atazanavir 300 mg and
(atazanavir 400 mg 1 gang
(atazanavir 400 mg once daily)
(atazanavir 400 mg 1 gang dagligt)
(atazanavir 400 mg once daily)
(atazanavir 400 mg 1 gang dagligt,
(atazanavir 400 mg once daily,
(atazanavir 400 mg som enkeltdosis)
(atazanavir 400 mg single dose)
(b) Cimzia administeret hver 4. uge forudgået af en støddosis på 400 mg ved uge 0, 2 og 4 (c) Hos personer med psoriasis på mindst 3% af legemesoverfladen (BSA) ved baseline
(b) Cimzia administered every 4 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 (c) In subjects with at least 3% psoriasis BSA at Baseline
(baseret på eliminationsvejen
on elimination pathway of
(BCR-ABL ≤0,0032% på den internationale skala), %
(BCR-ABL ≤0.0032% on the International Scale),
(Bedste responsrate)
(Best Response Rate)
(Bedste samlede responsrate CR/PR)
Best Overall Response Rate (CR/PR)
(Bekræftet3) [95 % CI]
Complete (Confirmed3) [95% CI]
(Bekræftet3) [95% CI]
(Confirmed3) [95% CI]
(Bemærk, at selv om kontrolindstillingerne på vandbadet og varmeblokkene indstilles til forskellige temperaturniveauer, vil temperaturen på indholdet i hætteglassene ligge inden for det samme område (55 C-60 °C)).
(Please note that whilst the control settings on the water bath and heat block are set to different levels the temperature of the vial contents are in the same range (55°C-60°C)).
(Bemærk: Den opblandede suspension bør rystes forsigtigt inden administration for at minimere tendensen til skumdannelse)-
(Note: This compounded suspension should be gently shaken prior to administration to minimise the tendency for air entrapment.)
(bl.a. forekom svimmelhed,
Simeprevir:
(BLISTER/ 14, 28 eller 84 tabletter)
(BLISTER/ 7, 14, 28 or 84 tablets)
(BLISTER/ 30, 50, 50x1, 90 eller 100 tabletter)
BLISTER/30, 50, 50x1, 90 or 100 tablets
(BLISTER/ 30, 50x1, 90 eller 100 tabletter)
BLISTER/30, 50x1, 90 or 100 tablets
(BLISTER/ 30x1, 50x1, 90x1 og 100 tabletter)
BLISTER / 30, 30x1, 50x1, 90x1 and 100x1 tablets
(BLISTER/ 7, 14, 28 eller 84 tabletter)
(BLISTER/ 7, 14, 28 or 84 tablets)
(BLISTER/ 7, 14, 28 eller 84 tabletter)
BLISTER / 14, 28 and 84 tablets
(Blister/pakninger med 30, 50x1, 90 eller 100 tabletter)
BLISTER/Boxes of 30, 50x1, 90 or 100 tablets
(Blisterkort med 7, 14, 28, 30, 50, 56, 84, 90 eller 100 filmovertrukne tabletter)
BLISTERS containing 7, 14, 28, 30, 50, 56, 84, 90 or 100 film-coated tablets
(blue box information anføres herpå)
(Contains blue box)
(blue box information anføres ikke)
(Does not contain blue box)
(buprenorphin/naloxon 8/2 –
(buprenorphine/naloxone 8/2
(Child-Pugh klasse C).Studier af cancerpatienter ekskluderede patienter med ALAT eller ASAT >2,5 x den øvre referenceværdi, eller hvis levermetastaser var årsag til tallene >5,0 x den øvre referenceværdi.
Studies in cancer patients have excluded patients with ALT or AST >2.5 x ULN (upper limit of normal) or, if due to liver metastasis, >5.0 x ULN.
(ciclosporin 100 mg enkeltdosis +
(cyclosporine 100 mg single dose +
(CYP1A2-substrat)
(CYP1A2 substrate)
(CYP2C9-, CYP2C19- og
[CYP2C9, CYP2C19 and CYP3A4
(CYP2C9-substrat)
(CYP2C9 substrate)
(CYP2D6 og CYP3A-
(CYP2D6 and
(CYP2D6-hæmning og/eller P-gp)
(CYP2D6 inhibition and/or P-gp)
(CYP2D6-substrat)
(CYP2D6 substrate)
(CYP3A- og OATPB1- hæmning)
(CYP3A and OATPB1
(CYP3A- og/eller P- glykoproteinhæmning)
(CYP3A and/ or P-glycoprotein inhibition)
(CYP3A-enzyminduktion)
(CYP3A enzyme induction)
(CYP3A-hæmning og/eller P-
(CYP3A inhibition and/or P-gp
(CYP3A-hæmning – indvirkning
(CYP3A inhibition - effect on
(CYP3A-hæmning – indvirkning
(CYP3A inhibition – effect on
(CYP3A-hæmning – indvirkning på quetiapin)
(CYP3A inhibition – effect on
(CYP3A-induktion –
(CYP3A induction - effect on
(CYP3A4-induktion)
(CYP3A4 inhibition)
(CYP3A4-induktion)
(UGT1A1 induction)
(CYP3A4-induktion)
:S25% (CYP3A4 enzyme induction)
(CYP3A4-induktion)
Interaction not studied.
(CYP3A4-induktion)
≤25% (CYP3A4 enzyme induction)
(CYP3A4-substrat)
(CYP3A4 substrate)
(CYP3A4/5-hæmning)
(CYP3A4/5 inhibition)
(CYP3A4/5-induktion)
(CYP3A4/5 induction)
(d) Komplet analysesæt NA = Ikke tilgængelig
(d) Full Analysis Set NA = not available
(darunavir 600 mg / ritonavir
(darunavir 600 mg / ritonavir 100 mg
(dels på grund af OATP1B- og
(due in part to OATP1B and CYP3A
(disse fænomener
cholestatic
(Disse kan forekomme hos flere end 1 bruger ud af 10) kvalme, opkastning, udslæt og feber.
(These can affect more than 1 user in 10) nausea, vomiting, rash and fever.